Asthika Goonewardene

Daina Graybosch

Leland Gershell

Stephen Willey

Tony Butler

Charles Wallace

Dana Gravesh

Karina Rabayeva

Keaton Wiley

- Compugen announced a **management transition**, with **Eran Ophir** stepping up as President and CEO, and **Anat Cohen-Dayag** moving to Executive Chairperson.  **[1119774_2145646_0]** **[1119774_2145646_2]** 
- The company reported a **stable cash balance of $94 million** as of **June 30**, with an expected cash runway into **2027**.  **[1119774_2145646_1]** 
- Compugen is eligible for **over $1 billion in future milestones** from its collaborations, including **mid-single-digit tiered royalties** on AstraZeneca's rifleucostamid (predicted **>$5 billion** in sales) and up to **$758 million in additional milestones** plus **single-digit to low double-digit tiered royalties** from Gilead's GS0321.  **[1119774_2145646_1]** 
- The company initiated the **MYO variant study** for its lead asset, **COM701**, in platinum-sensitive ovarian cancer, with a **readout expected in the second half of 2026**.  **[1119774_2145646_1]** **[1119774_2145646_2]**

Compugen Announces CEO Transition, Financial Position, and Pipeline Updates

COMPUGEN (CGEN)